Frequency of anti-nuclear antibodies in multiple sclerosis

Area of Science:

• Immunology
• Neurology
• Autoimmunity

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
• The presence and significance of anti-nuclear antibodies (ANA) in MS patients without other autoimmune conditions are not fully understood.
• Systemic lupus erythematosus (SLE) is a condition often associated with ANA.

Purpose of the Study:

• To investigate the prevalence of ANA in patients diagnosed with multiple sclerosis.
• To determine if ANA positivity in MS patients correlates with disease course (relapsing-remitting vs. chronic progressive).
• To assess the potential implications of ANA in the context of MS pathophysiology, excluding SLE.

Main Methods:

• Retrospective chart review of 173 patients with definite multiple sclerosis.
• Categorization of MS patients into relapsing-remitting (n=150) and chronic progressive (n=23) subtypes.
• Analysis of patient records for the presence of anti-nuclear antibodies (ANA), excluding those with a diagnosis of systemic lupus erythematosus.

Main Results:

• Anti-nuclear antibodies (ANA) were detected in 26.7% of relapsing-remitting MS patients.
• ANA were found in 30.4% of chronic progressive MS patients.
• Patients with MS and ANA did not have a diagnosis of systemic lupus erythematosus.

Conclusions:

• A notable percentage of multiple sclerosis patients exhibit anti-nuclear antibodies (ANA).
• The presence of ANA in MS patients without SLE is likely indicative of systemic immune dysregulation.
• ANA are considered false-positive in the context of MS and may not play a direct pathogenic role in the disease.